Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL).
SKU | RCLST506511 |
---|---|
CAS number | 1420477-60-6 |
Molecular Formula | C26H23N7O2 |
Catalog Number | RCLST506511 |
Chemical Name | Acalabrutinib |
Molecular Weight | 465.51 |
Solubility | DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) |
Stability | No Data Available |
Appearance | Light Yellow Solid |
Storage Condition | Refrigerator |